{"disease":{"id":"geographic-atrophy","name":"geographic atrophy"},"drugs":{"marketed":[{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy (GA) secondary to AMD","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"avacincaptad-pegol-sodium","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"AVACINCAPTAD PEGOL SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"Complement Inhibitors","quality_score":24,"revenue":null,"mechanism":""},{"drug_id":"avacincaptad-pegol","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Izervay","generic_name":"AVACINCAPTAD PEGOL","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Izervay works by binding to and inhibiting the activity of Complement C5, a protein involved in the immune response."},{"drug_id":"avacincaptad","indication_name":"Geographic atrophy secondary to age-related macular degeneration","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avacincaptad","company_name":"Aviceda Therapeutics, Inc.","drug_phase":"marketed","molecular_target":"Complement C5","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":4,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05891275","title":"Patients With Geographic Atrophy and Their Patient Journey in the United States (US)","phase":"","overall_status":"COMPLETED","enrollment_count":68563,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT06779773","title":"A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":false},{"nct_id":"NCT02745119","title":"Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":994,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT02247531","title":"A Study Investigating the Safety and Efficacy of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":975,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT06541704","title":"A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":975,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT02247479","title":"A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":906,"lead_sponsor_name":"Hoffmann-La Roche","has_results":true},{"nct_id":"NCT04770545","title":"An Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan (APL-2) in Subjects With Geographic Atrophy Secondary to AMD","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":792,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT06510816","title":"A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections of Vonaprument (Formerly ANX007) in Participants With Geographic Atrophy (GA)","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":659,"lead_sponsor_name":"Annexon, Inc.","has_results":false},{"nct_id":"NCT03525613","title":"A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":637,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03525600","title":"Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":621,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT04435366","title":"A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":448,"lead_sponsor_name":"IVERIC bio, Inc.","has_results":true},{"nct_id":"NCT05949593","title":"Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":429,"lead_sponsor_name":"Belite Bio, Inc","has_results":false},{"nct_id":"NCT03972709","title":"A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":372,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT05019521","title":"A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":365,"lead_sponsor_name":"Alexion Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT03815825","title":"GOLDEN STUDY: A Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRx in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":332,"lead_sponsor_name":"Ionis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT04465955","title":"A Study of NGM621 in Participants With Geographic Atrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":320,"lead_sponsor_name":"NGM Biopharmaceuticals, Inc","has_results":true},{"nct_id":"NCT02087085","title":"A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":310,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT05811351","title":"A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":305,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT02479386","title":"A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"","overall_status":"TERMINATED","enrollment_count":296,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT02686658","title":"Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":286,"lead_sponsor_name":"IVERIC bio, Inc.","has_results":true},{"nct_id":"NCT05536297","title":"Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":278,"lead_sponsor_name":"Astellas Pharma Global Development, Inc.","has_results":true},{"nct_id":"NCT06635148","title":"A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":274,"lead_sponsor_name":"Janssen Research & Development, LLC","has_results":false},{"nct_id":"NCT07441642","title":"A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":272,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04656561","title":"A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":270,"lead_sponsor_name":"Annexon, Inc.","has_results":false},{"nct_id":"NCT06499571","title":"Geographic Atrophy Long-Terms Outcomes Study","phase":"","overall_status":"COMPLETED","enrollment_count":255,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT05797896","title":"Investigating Geographic Atrophy Insights (i-GAIN) Natural History Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":250,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT02503332","title":"Study of Pegcetacoplan (APL-2) Therapy in Patients With Geographic Atrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":246,"lead_sponsor_name":"Apellis Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT02399072","title":"A Study of Disease Progression in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"","overall_status":"TERMINATED","enrollment_count":202,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06722157","title":"A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":202,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT03845582","title":"Phase 2/3 Study of ALK-001 in Geographic Atrophy","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Alkeus Pharmaceuticals, Inc.","has_results":true},{"nct_id":"NCT01602120","title":"An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":159,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT01527500","title":"Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":158,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT07029945","title":"A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":152,"lead_sponsor_name":"Biojiva LLC","has_results":false},{"nct_id":"NCT06769048","title":"A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT04607148","title":"A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":144,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT06961370","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":132,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT06375239","title":"Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","phase":"","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Ray Therapeutics, Inc.","has_results":false},{"nct_id":"NCT02515942","title":"CLG561 Proof-of-Concept Study as a Monotherapy and in Combination With LFG316 in Subjects With Geographic Atrophy (GA)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Alcon Research","has_results":true},{"nct_id":"NCT06659549","title":"A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":110,"lead_sponsor_name":"Galimedix Therapeutics Inc","has_results":false},{"nct_id":"NCT07215234","title":"A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":104,"lead_sponsor_name":"Sanofi","has_results":false},{"nct_id":"NCT06662162","title":"Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration","phase":"NA","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"i-Lumen Scientific AUS PTY LTD","has_results":false},{"nct_id":"NCT02288559","title":"A Study of Lampalizumab Intravitreal Injections Administered Every Two Weeks or Every Four Weeks to Participants With Geographic Atrophy","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":96,"lead_sponsor_name":"Genentech, Inc.","has_results":true},{"nct_id":"NCT03894020","title":"GTSCOPE - To Evaluate the Natural Progression of Dry Age-related Macular Degeneration (AMD)","phase":"","overall_status":"TERMINATED","enrollment_count":83,"lead_sponsor_name":"Gyroscope Therapeutics Limited","has_results":false},{"nct_id":"NCT07144137","title":"A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)","phase":"","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT07392255","title":"An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"Complement Therapeutics","has_results":false},{"nct_id":"NCT05961332","title":"COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy","phase":"NA","overall_status":"COMPLETED","enrollment_count":62,"lead_sponsor_name":"University of Wisconsin, Madison","has_results":false},{"nct_id":"NCT04643886","title":"A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":62,"lead_sponsor_name":"Gemini Therapeutics, Inc.","has_results":false},{"nct_id":"NCT06765980","title":"A Study to Evaluate KRIYA-825 (VV-14295) in Adults With Geographic Atrophy Secondary to Age-related Macular Degeneration","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Kriya Therapeutics, Inc.","has_results":false},{"nct_id":"NCT05626114","title":"A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"Genentech, Inc.","has_results":false},{"nct_id":"NCT06018558","title":"Study to Assess the Safety and Efficacy of OCU410 for Geographic Atrophy","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Ocugen","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}